drugset / Trial / NCT05971537

Clinical Trial on Antibiotic-Lock in Tenckhoff Catheter for Relasping and Repeat Peritonitis

NCT05971537

Phase 4 Recruiting 46 enrolled Alice Ho Miu Ling Nethersole Hospital
RandomizedCrossoverOpen-labelTreatment

Summary

Biofilm formation is an important cause of catheter-related infection. In hemodialysis, use of an antibiotic-lock has been proven to be effective to manage such a complication with preservation of the central venous catheter. In peritoneal dialysis, while biofilm has been implicated in relapsing and repeat peritonitis, both of which are caused by the identical bacteria as in their preceding peritonitis episode, no adjunctive measure has been proven to be effective to eradicate the biofilm bacteria. As a result, Tenckhoff catheter removal is the only recommended option for the patients suffering from relapsing or repeat peritonitis. In this study, the investigators are going to investigate whether the use of an antibiotic-lock can be useful to eradicate the biofilm in the Tenckhoff catheter to prevent future episodes of peritonitis caused by the same organism.

Timeline

Start
2023-06-15
Primary completion
2026-10
Completion
2026-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cefazolin Small molecule 10 mg/ml Other
Comparator Ceftazidime Small molecule 10 mg/ml Other
Comparator Gentamicin Small molecule 5 mg/ml Other
Comparator IMIPENEM ANHYDROUS Small molecule 50 mg/ml Other
Comparator Vancomycin Other / unclassified 10 mg/ml Other